研究单位：[1]Huabo Biopharm Co., Ltd.[2]Jiangmen Central Hospital,Jiangmen,Guangdong,China[3]Nanyang First People''s Hospital,Nanyang,Henan,China[4]Beijing Friendship Hospital,Beijing,China[5]China-Japan Friendship hospital,Beijing,China[6]Peking University People''s Hospital,Beijing,China[7]The First Affiliated Hospital of Bengbu Medical College,Bengbu,China[8]Jilin University Second Hospital,Chang chun,China[9]The first hospital of Jilin University,Chang chun,China[10]Xiangya Hospital of Central South University,Changsha,China[11]Affiliated Hospital of Chengde Medical University,Chengde,China[12]Sichuan Provincial People''s Hospital,Chengdu,China[13]West China Hospital of Sichuan University,Chengdu,China[14]Chongqing Traditional Chinese Medicine Hospital,Chongqing,China[15]Dongguan People''s Hospital,Dongguan,China[16]The First Affiliated Hospital of Fujian Medical University,Fuzhou,China[17]Dermatology Hospital of Southern Medical University,Guangzhou,China[18]Guangdong Provincial People''s Hospital,Guangzhou,China[19]Hangzhou First People''s Hospital,Hangzhou,China[20]Hangzhou Third People''s Hospital,Hangzhou,China[21]The First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,China[22]The Second Affiliated Hospital of Harbin Medical University,Harbin,China[23]The Second Affiliated Hospital of Anhui Medical University,Hefei,China[24]Jiaxing First Hospital,Jiaxing,China[25]Shandong Dermatology Hospital,Jinan,China[26]Jining First People''s Hospital,Jining,China[27]The First Affiliated Hospital of Kunming Medical University,Kunming,China[28]The Second Affiliated Hospital of Kunming Medical University,Kunming,China[29]The Second Affiliated Hospital of Henan University of Science and Technology,Luoyang,China[30]Dermatology Hospital of Jiangxi Province,Nanchang,China[31]The Second Affiliated Hospital of Nanchang University,Nanchang,China[32]Jiangsu University Affiliated Hospital,Nanjing,China[33]Ningbo Second Hospital,Ningbo,China[34]Shanghai Dermatology Hospital,Shanghai,China[35]People''s Hospital of Liaoning Province,Shenyang,China[36]Shenzhen People''s Hospital,Shenzhen,China[37]Shiyan People''s Hospital,Shiyan,China[38]The Second Hospital of Shanxi Medical University,Taiyuan,China[39]Wenzhou Medical University Affiliated First Hospital,Wenzhou,China[40]Wuhan University People''s Hospital,Wuhan,China[41]The First Affiliated Hospital of Wannan Medical College,Wuhu,China[42]Wuxi Second People''s Hospital,Wuxi,China[43]The Second Affiliated Hospital of Xi''an Jiaotong University,Xi''an,China[44]Xingtai People''s Hospital,Xingtai,China[45]Yangjiang People''s Hospital,Yangjiang,China
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in the treatment of moderate to severe plaque psoriasis in adults.
